Due to corporate strategic adjustment.

This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.

This study is a single-arm, mult-center clinical trial of dose escalation and dose expansion, primarily aimed at evaluating the safety, tolerability, and preliminary efficacy of BAFFR CAR-T cell infusion in subjects with relapsed/refractory B-cell tumors.

Inclusion Criteria:

1. The patient or their guardian understands and voluntarily signs the informed consent form and expects to complete the follow-up examinations and treatments of the research protocol；

2. Age 18-85 years old (inclusive), gender unrestricted;

3. The definition of refractory in patients with B-cell lymphoma is as follows:

   • no response to the most recent treatment, including:

     1. the best response to the most recent treatment regimen is disease progression (PD);
     2. or the best response to the most recent treatment is stable disease (SD) and the duration does not exceed 6 months after the last administration;

   • or unsuitable or unwilling to undergo autologous hematopoietic stem cell transplantation (ASCT), or ASCT refractory, including:

     1. disease progression or recurrence within ≤ 12 months after ASCT;
     2. or if salvage treatment is administered after ASCT, the subject must have no response or relapse after the last treatment;

4. B-ALL/LBL patients, refractory definition: failure to achieve complete remission (bone marrow blast cells ≥ 5% or persistence of extramedullary lesions) after standard induction or salvage therapy, or early relapse (<12 months) after remission with no response to re-induction therapy.

5. Patients with relapsed/refractory acute B-cell lymphoma who have previously been treated with anti-CD20 targeted agents (unless documented as CD20 negative) and anthracycline agents;

6. Patients with lymphoma must have at least one measurable lesion from baseline according to the revised IWG criteria for assessing the efficacy of malignant lymphoma；

7. The organ functions well；

8. ECOG performance status score 0-3 and estimated survival time greater than 3 months.

Exclusion Criteria:

1. Have other malignant tumors within 3 years before screening, excluding adequately treated cervical carcinoma in situ, papillary thyroid carcinoma, basal cell or squamous cell skin cancer, local prostate cancer after radical prostatectomy, and ductal carcinoma in situ after radical prostatectomy.

2. Hepatitis B surface antigen (HBsAg) positive, hepatitis B core antibody (HBcAb) positive and peripheral blood HBV-DNA higher than the detection limit; Hepatitis C virus (HCV) antibody positive; Persons with human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive cases; EBV-DNA positive patients; The syphilis antibody was positive.

3. Those with a history of anaphylaxis [A history of anaphylaxis was defined as an allergic reaction of grade 2 or higher, in which any of the following clinical manifestations occurred: Airway obstruction (rhinorrhea, cough, stridor, dyspnea), Tachycardia, Hypotension, Arrhythmia, Gastrointestinal symptoms (nausea, vomiting), Incontinence, Laryngeal edema, Bronchospasm, Cyanosis, Shock, Respiratory, cardiac arrest] or known to be allergic to any of the drug active ingredients, excipents, or mouse-derived products or xenoproteins included in this trial (including the lymphatic cells clearance protocol).

4. Have severe cardiac disease, including but not limited to severe arrhythmia, unstable angina, massive myocardial infarction, New York Heart Association class III or IV cardiac dysfunction, and refractory hypertension.

5. Previous organ transplantation or preparation for organ transplantation (excluding hematopoietic stem cell transplantation).

6. Active autoimmune or inflammatory diseases (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically significant active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES)).

7. Patients with cancer emergencies (such as spinal cord compression, intestinal obstruction, leukostasis, tumor lysis syndrome, etc.) requiring emergency treatment before screening or reinfusion.

8. Presence of uncontrolled bacterial, fungal, viral, or other infection requiring antibiotic treatment.

9. Patients who had undergone major surgery (excluding diagnostic surgery and biopsy) within 4 weeks before lymphatic cells clearance or planned to undergo major surgery during the study period, or who had not fully healed the surgical wound before enrollment.

10. Persons with severe mental illness.

11. Within 1 week before the collection of peripheral blood mononuclear cells (PBMC), patients who use granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF) and other hematopoietic cytokine drugs that have an impact on the patient's blood picture (if it is a long-acting preparation, it is 2 weeks) and have an impact on cell preparation as judged by the investigator .

12. Within 2 weeks before PBMC collection, patients were receiving hormonal or immunosuppressive drugs that were judged by the investigator to have an effect on cell production.

    1. hormone: subjects who were receiving systemic steroid therapy within 2 weeks before PBMC collection and who required long-term systemic steroid therapy (except inhaled or topical use) as judged by the investigator during the treatment.
    2. Immunosuppressive agents: those who were receiving immunosuppressive agents within 2 weeks before PBMC collection.

13. Vaccination with live (attenuated) virus vaccine within 4 weeks prior to screening.

14. Alcoholics or those with a history of substance abuse.

15. Patients who, in the investigator's judgment and/or clinical criteria, have contraindications to any study procedure or other medical conditions that may put them at unacceptable risk.